Immune Thrombocytopenia (ITP)
Immune Thrombocytopenia (ITP) is a chronic autoimmune disorder that affects the blood. It happens when the body’s immune system mistakenly targets and destroys its own platelets, which are the small blood particles essential for normal blood clotting. As platelet counts drop, patients become more vulnerable to bruising, bleeding episodes, or, in severe cases, dangerous hemorrhaging.
Beyond bleeding risk, ITP can also cause significant fatigue and impact daily quality of life. The disease often follows an unpredictable course, with periods of remission and relapse and because the condition is chronic, many patients require ongoing monitoring.
Treatment for ITP is aimed at increasing platelet counts and reducing the risk of serious bleeding events.
Unmet need
There is a high unmet need in ITP, and patients are limited in their treatment options. The majority of patients are poorly managed with steroids, and many experience disease progression on standard second-line therapy. While not approved for ITP, rituximab is commonly used and has demonstrated the potential for long-term disease remission, though only ~20% of patients maintain remission over time.
~85k patients in
the US alone
~80% of patients fail first-line steroids; ~40% progress
after second-line TPO-RAs
~80% of patients
relapse on rituximab
How budoprutug may be able to help
B cell-depleting therapies such as budoprutug are a promising potential treatment approach for ITP because they work to eliminate the problematic B cells that produce the autoantibodies that cause the disease.
Budoprutug targets CD19, which has broad expression across many types of B cells, including autoantibody producing cells.
A Phase 1b/2a study evaluating the safety, tolerability, PK, PD, and preliminary clinical effectiveness of budoprutug in patients with ITP is currently ongoing.
Support and Resources
Living with ITP can be challenging, but you are not alone. There are organizations, support groups, and trusted resources that can help you better understand your condition, connect with others, and find the support you need.
Tracey’s Story
Living with Immune Thrombocytopenia
At 51, Tracey thought her strange bruises were just part of aging—until tests revealed a dangerously low platelet count and a diagnosis of ITP. After years of failed treatments and unpredictable health, she found hope and community through the Platelet Disorder Support Association. Today, she’s a passionate advocate, leading local support efforts and raising awareness for better treatments and understanding of ITP.
Learn More